survivin peptide is expressed in almost all types of malignancies - SurVaxM side effects Survivin-based recombinant overlapping peptides (ROPs Unlocking the Potential of Survivin Peptide in Cancer Therapy

Survodutidepeptide The survivin peptide has emerged as a significant area of research in oncology, offering a promising avenue for novel cancer therapies. Survivin, also known as BIRC5, is a crucial protein belonging to the inhibitors of apoptosis proteins (IAPs) family. This protein plays a vital role in regulating cell division and critically, in preventing programmed cell death, or apoptosis. Its dysregulation is a hallmark of many cancers, leading to enhanced tumor survival and resistance to conventional treatments. Due to its overexpression in various malignancies and its relative absence in normal adult tissues, Survivin is an important TAA (tumor-associated antigen) and a prime target for therapeutic interventions.PepTivator®Survivin 1is a peptide pool that consists mainly of 15-mer peptides with 11-amino acid (aa) overlap, covering the complete sequence of the human ...

The development of survivin peptide-based strategies aims to harness the immune system to combat cancer. These strategies often involve using fragments of the survivin protein to stimulate an anti-tumor immune response. For instance, PepTivator® Survivin 1, human, is a peptide pool composed of 15-mer peptides with an 11-amino acid overlap, covering the entire sequence of human survivin. Similarly, PepMix Human (Survivin) Overlapping Peptide Pool and Peptide pool of 33 overlapping peptides are derived from peptide scans of Baculoviral IAP repeat-containing protein (BIRC)5 (Survivin). These pools are designed to present various epitopes of survivin to the immune system.

Research into survivin peptide vaccines has shown considerable promise.This phase I trial studies the side effects ofsurvivin long peptide vaccineand how it works with the immune system in treating patients with neuroendocrine ... The conjugated survivin peptide mimic, known as SurVaxM (SVN53-67/M57-KLH), has demonstrated the ability to stimulate an anti-tumor immune response against murine glioma and has been explored in clinical trials. A survivin long peptide vaccine, such as SurVaxM, is being investigated for its safety and efficacy in various cancers.Survivin Peptide - #AF6017-BP Clinical studies, including those evaluating the survivin long peptide vaccine in treating neuroendocrine tumors, are ongoing. Furthermore, Survivin-based recombinant overlapping peptides (ROPs) are being studied for their vaccine immunogenicity. For example, a study by W Wijaya in 2026 aimed to evaluate the safety and tolerability of OVM-200, a survivin recombinant overlapping peptide (ROP) vaccine, in patients with non-small cell lung cancer (NSCLC), ovarian cancer, and prostate cancerSurvivin‐Based Recombinant Overlapping Peptides Induce T ....

Beyond vaccination, specific survivin peptides are also being utilized in various research and therapeutic contexts作者：RA Fenstermaker·2016·被引用次数：194—Survivin is an anti-apoptotic proteinthat is highly expressed in many cancers, including malignant gliomas. Preclinical studies established .... For example, the Survivin Peptide (LMLGEFLKL), a modified recombinant nonapeptide derived from the anti-apoptosis protein survivin, has shown potential immunopotentiating and antineoplastic effects作者：SM Schmidt·2003·被引用次数：364—Survivin, a member of the inhibitor of apoptosis protein family,is expressed in almost all types of malignancies, making this protein a useful tool for the .... Another example is the Survivin 2B Peptide (AYACNTSTL), which is a specific antigenic peptide recognized by CD8+ cytotoxic T lymphocytes (CTLs) and is employed in cancer immunotherapyA modified recombinant nonapeptide (LMLGEFLKL) derived from the anti-apoptosis protein survivin with potential immunopotentiating and antineoplastic .... The identification of a survivin-derived peptide that induces specific immune responses is crucial for developing targeted therapies. Researchers have identified a promiscuous survivin peptide that induces a robust CD4+ T-cell response, highlighting the diverse immunomodulatory capabilities of these peptides.

The mechanism of action for these survivin peptides often involves engaging T cells. For instance, specific peptides like Survivin peptide TLPPAWQPFL (HLA-A*0201) are synthesized as they are presented by the MHC class I HLA-A*0201 allele and can be used for targeted in vitro studies. These peptides are valuable for the stimulation of antigen-specific T cells in various assays, including ELISPOT, ICS, cytotoxicity, or proliferation assaysSurvivin Blocking Peptide for PRS2237. The ability of these peptides to induce T cell responses is critical for their therapeutic potential.

The significance of Survivin extends to its role as a biomarkerPool of 33 peptidesderived from a peptide scan through Baculoviral IAP repeat-containing protein (BIRC)5 (Surivin) (Swiss-Prot ID: O15392) of Human.. Survivin is a molecular biomarker in cancer, and its presence and levels can correlate with disease progression and patient outcomes.Peptide-Based Agents for Cancer Treatment - PMC - NIH As a 16 kDa anti-apoptotic protein, its overexpression is linked to increased tumor recurrence and chemotherapy resistance. This makes it a valuable target not only for direct therapeutic intervention but also for diagnostic and prognostic purposes.

The research landscape also includes the development of blocking peptidesSurvivin Peptide - #AF6017-BP. Survivin Blocking Peptide #1037, for instance, is designed to inhibit the function of survivin. Similarly, Survivin Blocking Peptide for SAB3500269 and Survivin Blocking Peptide for PRS2237 are reagents used to study the role of survivin or to block its antibody bindingSurvivin Peptide (LMLGEFLKL). These blocking peptides, which can be derived from specific regions like the 13 amino acids near the carboxy terminus of mouse Survivin, help researchers understand the protein's interactions and functions.

The journey of survivin peptide research is ongoing, with continuous efforts to refine vaccine strategies and identify novel peptide epitopes. The fundamental understanding that survivin is directly associated with tumor survival fuels the relentless pursuit of effective peptide-based cancer immunotherapies. As research progresses, the potential of survivin peptide in revolutionizing cancer treatment becomes increasingly evident, offering hope for improved patient outcomes in various malignancies where Survivin is expressed in almost all types of malignancies.